(NASDAQ: EVGN) Evogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.39%.
Evogene's earnings in 2026 is -$11,768,000.On average, 3 Wall Street analysts forecast EVGN's earnings for 2026 to be -$15,931,529, with the lowest EVGN earnings forecast at -$15,306,763, and the highest EVGN earnings forecast at -$16,400,103. On average, 3 Wall Street analysts forecast EVGN's earnings for 2027 to be -$8,496,815, with the lowest EVGN earnings forecast at -$8,163,607, and the highest EVGN earnings forecast at -$8,746,722.
In 2028, EVGN is forecast to generate -$5,841,561 in earnings, with the lowest earnings forecast at -$5,612,480 and the highest earnings forecast at -$6,013,371.